JPWO2021182571A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021182571A5
JPWO2021182571A5 JP2021531941A JP2021531941A JPWO2021182571A5 JP WO2021182571 A5 JPWO2021182571 A5 JP WO2021182571A5 JP 2021531941 A JP2021531941 A JP 2021531941A JP 2021531941 A JP2021531941 A JP 2021531941A JP WO2021182571 A5 JPWO2021182571 A5 JP WO2021182571A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021531941A
Other languages
English (en)
Japanese (ja)
Other versions
JP7715041B2 (ja
JPWO2021182571A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/009796 external-priority patent/WO2021182571A1/ja
Publication of JPWO2021182571A1 publication Critical patent/JPWO2021182571A1/ja
Publication of JPWO2021182571A5 publication Critical patent/JPWO2021182571A5/ja
Application granted granted Critical
Publication of JP7715041B2 publication Critical patent/JP7715041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021531941A 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品 Active JP7715041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020043019 2020-03-12
JP2020043019 2020-03-12
PCT/JP2021/009796 WO2021182571A1 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Publications (3)

Publication Number Publication Date
JPWO2021182571A1 JPWO2021182571A1 (https=) 2021-09-16
JPWO2021182571A5 true JPWO2021182571A5 (https=) 2024-02-28
JP7715041B2 JP7715041B2 (ja) 2025-07-30

Family

ID=77671704

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021531941A Active JP7715041B2 (ja) 2020-03-12 2021-03-11 癌の治療及び/又は予防のための医薬品

Country Status (7)

Country Link
US (1) US20230165957A1 (https=)
EP (1) EP4119158A4 (https=)
JP (1) JP7715041B2 (https=)
KR (1) KR20220152309A (https=)
BR (1) BR112022018166A2 (https=)
CA (1) CA3175127A1 (https=)
WO (1) WO2021182571A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911926A2 (pt) * 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
US20250228937A1 (en) * 2021-06-23 2025-07-17 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
DK2532680T3 (da) * 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
CA2788545C (en) * 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
US9115200B2 (en) * 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス,インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
RU2595400C2 (ru) * 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
US9260513B2 (en) * 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR20200110452A (ko) * 2018-02-12 2020-09-23 어레이 바이오파마 인크. 담도암을 치료하기 위한 방법 및 조합 요법
AU2019242520B2 (en) 2018-03-30 2026-02-26 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
JP2020043019A (ja) 2018-09-12 2020-03-19 トヨタ自動車株式会社 燃料電池

Similar Documents

Publication Publication Date Title
JPWO2021182573A5 (https=)
EP4582100A1 (en) Medicament for treatment and/or prevention of cancer
EP3777888A1 (en) Pharmaceutical composition for treatment and/or prevention of cancer
EP4119156A1 (en) Medicament for treatment and/or prevention of cancer
US20250228937A1 (en) Medicament for treatment and/or prevention of cancer
JPWO2021182571A5 (https=)
JPWO2021182574A5 (https=)
JPWO2021182570A5 (https=)
TW202128176A (zh) 使用蛋白精胺酸甲基轉移酶5(prmt5)抑制劑之每日一次癌症治療方案
CN111246881B (zh) Pd-1抗体用于治疗肿瘤的用途
JP7715041B2 (ja) 癌の治療及び/又は予防のための医薬品
JP7793986B2 (ja) 癌の治療及び/又は予防のための医薬品
JPWO2021182572A5 (https=)
US20230159635A1 (en) Medicament for treatment and/or prevention of cancer
JP7793985B2 (ja) 癌の治療及び/又は予防のための医薬品
US20260115267A1 (en) Methods of using anti-egf antibodies to augment the activity of braf and kras inhibitors
WO2019107341A1 (ja) オゾンナノバブルの抗がん剤
EP4360648A1 (en) Medicament for treatment and/or prevention of cancer
EP4582101A1 (en) Medicament for treatment and/or prevention of cancer
EP4578459A1 (en) Pharmaceutical product for treatment and/or prevention of cancer
EP4578458A1 (en) Medicament for treatment and/or prevention of cancer
EP4578457A1 (en) Pharmaceutical for treating and/or preventing cancer
EP4640235A1 (en) Medicament for treatment and/or prevention of cancer
WO2022189618A1 (en) Nitrogen-containing heterocycles as radiosensitizers